JDD February 2024 Issue Highlights
Explore the February 2024 issue of the Journal of Drugs in Dermatology! Discover groundbreaking research on topics such as novel treatments for melasma, advancements in psoriasis management, gene expression profile (GEP) testing for squamous cell carcinoma, pediatric vitiligo, and many more! Stay ahead of the curve with the latest insights from leading dermatology experts. Straight from the Editor …
Explore the February 2024 issue of the Journal of Drugs in Dermatology! Discover groundbreaking research on topics such as novel treatments for melasma, advancements in psoriasis management, gene expression profile (GEP) testing for squamous cell carcinoma, pediatric vitiligo, and many more! Stay ahead of the curve with the latest insights from leading dermatology experts. Straight from the Editor … 
The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen pl … 
With a special focus on the topic of psoriasis, check out highlights from the August issue of the Journal of Drugs in Dermatology (JDD) straight from the JDD Editor’s desk:
Consensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis delves into the expert guidance provided by the Psoriasis Expert Group (PEG), encompassing nine crucial statements that offer com … 
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Amit Garg, professor and founding chairman of the department of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Garg explains why it’s an exciting time in hidradenitis suppurativa, and how clinicians are using existing therapies in innovative ways. Watch as he explains the imp … 
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica … 